Denali Therapeutics Inc (NASDAQ:DNLI) major shareholder Douglas K. Bratton sold 122,077 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $23.94, for a total transaction of $2,922,523.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
DNLI opened at $23.70 on Wednesday. Denali Therapeutics Inc has a 1-year low of $12.39 and a 1-year high of $30.41. The company has a market cap of $2.50 billion, a price-to-earnings ratio of -10.77 and a beta of 1.88. The company’s fifty day moving average price is $25.23 and its two-hundred day moving average price is $21.76. The company has a current ratio of 12.70, a quick ratio of 12.70 and a debt-to-equity ratio of 0.12.
Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, May 7th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.02. Denali Therapeutics had a negative net margin of 825.96% and a negative return on equity of 46.48%. The company had revenue of $3.60 million during the quarter, compared to the consensus estimate of $5.93 million. As a group, equities analysts forecast that Denali Therapeutics Inc will post -2.44 earnings per share for the current fiscal year.
A number of research firms have issued reports on DNLI. Nomura Securities reissued a “buy” rating and issued a $35.00 price objective on shares of Denali Therapeutics in a report on Monday, March 9th. ValuEngine downgraded Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 1st. TheStreet upgraded Denali Therapeutics from a “d+” rating to a “c-” rating in a report on Wednesday, May 20th. Zacks Investment Research cut shares of Denali Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, June 22nd. Finally, Morgan Stanley cut their price target on Denali Therapeutics from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Wednesday, April 15th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Denali Therapeutics currently has an average rating of “Buy” and a consensus target price of $29.91.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Further Reading: What is the accumulation/distribution indicator?
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.